✦ LIBER ✦

O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Scribed by Vamvakas, L.; Androulakis, N.; Syrigos, K.; Polyzos, A.; Ziras, N.; Athanasiadis, A.; Kakolyris, S.; Tsousis, S.; Kouroussis, Ch.; Kalykaki, A.; Samonis, G.; Mavroudis, D.; Georgoulias, V.; Souglakos, J.

Book ID: 122933331
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 62 KB
Volume: 60
Category: Article
ISSN: 1040-8428
DOI: 10.1016/S1040-8428(13)70069-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FOLFOXIRI (folinic acid, 5-fluorouracil,

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Souglakos, J; Androulakis, N; Syrigos, K; Polyzos, A; Ziras, N; Athanasiadis, A; 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 128 KB

XELIRI-bevacizumab versus FOLFIRI-bevaci

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

✍ Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G El 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 286 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

P.40 Oral vinorelbine and gemcitabine (o

P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Agelidou, A.; Kotsakis, A.; Kakolyri 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB